The study took a retrospective look at children who had undergone clinically indicated endoscopy between October 2022 and October 2024. In these procedures, physicians obtained gastric biopsy samples that could be tested in two complementary ways. First, the team used polymerase chain reaction, or PCR, followed by Sanger sequencing, to search the bacterial genetic material for known resistance-associated variants in key genes. Second, they attempted to grow live bacteria from the biopsies in culture, and when that succeeded, they subjected the isolates to antimicrobial susceptibility testing, the traditional method of exposing bacteria to antibiotics and measuring whether the drugs inhibit growth.

Of the 145 children enrolled in the analysis, 128, or 88.3 percent, tested positive for H. pylori by PCR, while 92 yielded positive cultures. The phenotypic resistance figures that emerged from susceptibility testing were striking. Clarithromycin, a macrolide antibiotic that forms the backbone of many standard eradication regimens, failed to inhibit 82.6 percent of isolates. Metronidazole, another frequently used agent, was ineffective against 81.5 percent. Levofloxacin, a fluoroquinolone often held in reserve for second-line therapy, showed resistance in 29.3 percent of isolates. Most concerning of all, 72.8 percent of the cultured isolates were resistant to at least two of these antibiotics, a level of multidrug resistance that sharply narrows the menu of empirical options available to clinicians who must choose treatment before any laboratory results return.

The molecular side of the study focused on two genes with well-established roles in resistance. Mutations in the 23S ribosomal RNA gene are the principal drivers of clarithromycin resistance, altering the binding site on the bacterial ribosome so that the drug can no longer interfere with protein synthesis. Variants in gyrA, which encodes a subunit of the enzyme DNA gyrase, underpin levofloxacin resistance by changing the drug’s target in the bacterial replication machinery. When the researchers compared PCR-detected mutations in these genes against the phenotypic test results, the agreement was remarkably strong. For clarithromycin nonsusceptibility, molecular prediction achieved 98.8 percent sensitivity, 90.9 percent specificity, and 97.8 percent accuracy. For levofloxacin, the corresponding figures were 90.9 percent sensitivity, 97.7 percent specificity, and 95.5 percent accuracy.

Those performance statistics matter because they speak to a long-standing practical dilemma in pediatric gastroenterology. Culture-based susceptibility testing, while definitive, is slow, technically demanding, and not always successful; in this cohort, cultures were positive for only 92 of the 145 children despite nearly universal PCR positivity. Molecular testing, by contrast, can be completed quickly from biopsy material even when the organism cannot be grown, and it can detect heterogeneous mixtures of resistant and susceptible organisms within a single sample. The new data suggest that for clarithromycin and levofloxacin, the genetic readout is a close and reliable proxy for what the phenotype would show, making rapid PCR-based screening a realistic complement to culture in routine care.

The picture was less clear-cut for other antibiotics. The study’s authors note that molecular findings for agents beyond clarithromycin and levofloxacin were less readily interpretable, which reflects the messier biology of resistance to drugs such as metronidazole. Resistance to nitroimidazoles like metronidazole involves multiple genes, including those encoding enzymes that activate the drug inside the bacterial cell, and no single mutation reliably predicts failure. That biological complexity explains why the team did not claim equivalent molecular performance across the board, and why culture remains indispensable for antibiotics whose resistance mechanisms are polygenic or incompletely mapped.

Treatment outcomes provided the clinical payoff of the analysis. Among 97 children who received eradication therapy and completed follow-up, 86, or 88.7 percent, were cured as confirmed by the carbon-13 urea breath test, a noninvasive test in which the child drinks a labeled urea solution and breath samples reveal whether urease-producing bacteria remain in the stomach. Critically, the study linked resistance data to prescribing behavior: of the 84 culture-positive children who were treated, 80 received regimens that were concordant with the phenotypic susceptibility results. That alignment between laboratory findings and drug selection is precisely what the susceptibility-guided approach is meant to achieve, and the high eradication rate suggests it worked in practice.

The findings land in a field already wrestling with troubling regional and global trends. Systematic reviews cited by the authors document rising primary antibiotic resistance in H. pylori across the Asia-Pacific region and among children worldwide, with clarithromycin resistance in East Asian pediatric populations climbing to levels that undermine standard triple therapy. Updated joint guidelines from the European and North American pediatric gastroenterology societies, ESPGHAN and NASPGHAN, released in 2023, emphasize the importance of antimicrobial susceptibility testing where possible, and a 2025 study found that susceptibility-guided treatment outperformed empirical therapy in children. The new Chinese data add granular, genotype-to-phenotype-to-outcome evidence supporting that direction of travel.

For clinicians, the practical message is twofold. Where culture and susceptibility testing are available, they should inform regimen selection, particularly in settings where resistance prevalence is high enough that empirical choices are likely to miss. Where culture fails or delays are unacceptable, rapid molecular testing of 23S rRNA and gyrA can reliably flag clarithromycin and levofloxacin resistance, allowing physicians to steer away from doomed regimens before the first dose is given. The study also underscores the limits of either approach alone: molecular panels cannot yet substitute for phenotypic testing across all antibiotics, and culture cannot always be obtained. The complementary strategy demonstrated here, in which each method covers the other’s blind spots, achieved an eradication rate near 89 percent in a cohort with extraordinary baseline resistance.

The broader implications extend beyond a single hospital in Shenyang. H. pylori infects a substantial fraction of children globally, and childhood infection is the reservoir from which adult disease, including gastric cancer risk, ultimately springs. Every failed treatment course exposes the patient to unnecessary drugs, drives further resistance selection, and leaves the infection in place. As resistance rates continue to climb, the kind of paired molecular and phenotypic diagnostics validated in this study may shift from a research luxury to a standard of care, particularly in high-prevalence regions where empirical therapy has become a gamble. The authors’ demonstration that genetic screening closely mirrors phenotypic reality for the two most actionable resistance targets offers a concrete, technically grounded path toward smarter, faster, and more successful treatment of one of the world’s most persistent childhood infections.

Subject of Research: Antimicrobial resistance and molecular resistance prediction in pediatric Helicobacter pylori infection

Article Title: Antimicrobial resistance patterns, molecular resistance prediction, and treatment outcomes in pediatric Helicobacter pylori infection

Article References: Chen, Y., Gu, Z., Sun, M., Mao, Z., & Guo, J. (2026). Antimicrobial resistance patterns, molecular resistance prediction, and treatment outcomes in pediatric Helicobacter pylori infection. Pediatric Research. https://doi.org/10.1038/s41390-026-05435-0

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05435-0

Keywords: Helicobacter pylori, antimicrobial resistance, pediatrics, clarithromycin, metronidazole, levofloxacin, PCR, 23S rRNA, gyrA, eradication therapy, susceptibility testing, urea breath test

The scale of the investigation reflects the difficulty of working with organisms that are ubiquitous in soil and water. The researchers analyzed 193 clinical samples drawn from five distinct sources: 101 fecal samples, 21 nasal swabs, 13 trans-tracheal washes, 30 tissue specimens, and 28 blood samples. Each sample was processed through two parallel routes, direct polymerase chain reaction and culture-based isolation, a dual strategy designed to capture both organisms present in the sample at the time of collection and those capable of growing under laboratory conditions. Decontamination steps, essential when dealing with samples teeming with faster-growing environmental flora, were carefully applied to give the slow-growing mycobacteria a chance to emerge on culture media. The approach mirrors established diagnostic protocols for mycobacterial recovery from clinical material, where the balance between eliminating contaminants and preserving viable target organisms is notoriously delicate.

Identification proceeded in a tiered molecular fashion. Genus-level confirmation relied on PCR targeting the hsp65 gene, a workhorse marker in mycobacterial taxonomy that encodes a heat shock protein and allows discrimination of mycobacteria from other acid-fast organisms. Once the isolates were confirmed as members of the genus Mycobacterium and distinguished from the Mycobacterium tuberculosis complex, species-specific PCR assays were deployed to pin down exactly which non-tuberculous species had been recovered. This hierarchical approach, from broad genus screening to species-level resolution, is critical because the clinical and epidemiological significance of non-tuberculous mycobacteria varies enormously from one species to the next. In total, the workflow yielded eighteen confirmed non-tuberculous mycobacterial isolates, a modest but workable collection for downstream genetic analysis.

The species picture that emerged was strikingly lopsided. Mycobacterium vaccae accounted for two-thirds of the isolates, representing 66.7 percent of the confirmed collection. This organism, first described decades ago and long studied for its immunomodulatory properties, is a common inhabitant of soil, water, and dust, and its dominance in bovine samples underscores how readily environmental mycobacteria colonize or transit through livestock. The remaining isolates comprised other non-tuberculous species, though M. vaccae clearly set the tone of the collection. For veterinary diagnosticians, this predominance matters: when a bovine sample yields acid-fast organisms or tuberculosis-like lesions, the probability that the culprit is an environmental species rather than Mycobacterium bovis has direct consequences for how the finding is interpreted within national tuberculosis control frameworks.

With the isolates in hand, the team turned to the central question of the study: what resistance-associated genes do these bovine non-tuberculous mycobacteria carry? Four genes were selected for screening, each with a well-characterized role in drug resistance in Mycobacterium tuberculosis. The rpoB gene, encoding the beta subunit of RNA polymerase, is the principal target of rifampicin, and mutations within its resistance-determining region are the classic molecular signature of rifampicin resistance. The katG gene encodes catalase-peroxidase, the enzyme that activates the prodrug isoniazid, and disruptions in katG are strongly associated with high-level isoniazid resistance. The rpsL gene, encoding ribosomal protein S12, is implicated in streptomycin resistance, while gyrA, encoding the A subunit of DNA gyrase, harbors mutations in its quinolone resistance-determining region that confer fluoroquinolone resistance. Screening these four targets across the eighteen isolates provided a snapshot of the genetic resistance landscape in bovine non-tuberculous mycobacteria from the region.

The screening results revealed a clear hierarchy. The rpoB gene was the most frequently detected, present in 88.9 percent of the isolates, and its detection was mainly associated with Mycobacterium vaccae. The katG gene turned up in 16.7 percent of isolates, and the gyrA gene in just 5.6 percent, and notably both of these were found exclusively in M. vaccae. The rpsL gene, by contrast, was not amplified in any isolate, suggesting that streptomycin-associated genetic determinants, at least as targeted by the primers used, are absent from this collection. The pattern indicates that within this bovine sample set, genetic elements associated with resistance cluster heavily in one environmental species, raising questions about whether M. vaccae’s ecological lifestyle, including prolonged exposure to antimicrobial residues in agricultural environments, might shape its genetic repertoire.

Sequencing of selected amplicons added an important layer of nuance. When the researchers examined the hotspots of rpoB and katG, the regions where resistance-conferring mutations most commonly occur in Mycobacterium tuberculosis, they found no mutations at all. This is a meaningful negative result: the mere presence of a gene does not imply the presence of resistance-conferring variants within it. However, the story differed for gyrA. Sequence analysis of the quinolone resistance-determining region of gyrA revealed non-synonymous substitutions, meaning nucleotide changes that alter the encoded amino acid sequence of DNA gyrase. Whether these substitutions affect fluoroquinolone susceptibility in these isolates remains an open question, but their presence in the canonical resistance region of the enzyme is exactly the kind of finding that warrants closer phenotypic scrutiny.

The authors are careful, and rightly so, about what these results do and do not demonstrate. The detection of resistance-associated genes and even of amino acid substitutions reflects genotypic variation only. Because drug susceptibility testing was not performed on the isolates, the study cannot confirm phenotypic resistance to rifampicin, isoniazid, streptomycin, or fluoroquinolones. This distinction is fundamental in mycobacteriology. Genes such as rpoB and katG are essential housekeeping and metabolic genes present in virtually all mycobacteria; their detection by PCR says nothing about function unless the specific mutational hotspots are altered. Moreover, resistance mechanisms in non-tuberculous mycobacteria differ in important ways from those in the tuberculosis complex, involving intrinsic factors such as impermeable cell walls, efflux pumps, and species-specific enzymatic machinery, which means that extrapolating interpretive criteria from M. tuberculosis to environmental species is fraught with uncertainty.

Nevertheless, the study carries practical implications for animal health and public health alike. Non-tuberculous mycobacteria can produce tuberculosis-like lesions in bovines, and such lesions can trigger false-positive reactions in tuberculin skin testing, the backbone of bovine tuberculosis surveillance programs. Every misattributed lesion represents a potential misdiagnosis, with consequences ranging from unnecessary slaughter to missed transmission of true Mycobacterium bovis infection. By documenting which non-tuberculous species circulate in Indian cattle and buffaloes, and by beginning to map their resistance gene content, the researchers are building the species-level baseline that surveillance programs need to distinguish environmental noise from genuine tuberculosis signals. The finding that M. vaccae dominates the isolates gives diagnosticians a concrete expectation about what they are most likely to encounter when non-tuberculous organisms appear in bovine material.

The road forward, as the authors indicate, runs through phenotypic and species-specific analyses. Establishing the functional significance of the gyrA substitutions observed in M. vaccae will require correlating genotypes with measured minimum inhibitory concentrations of fluoroquinolones, and ideally with functional studies of the mutant gyrase enzymes. Broader panels of resistance genes, and ultimately whole-genome sequencing, could reveal the full complement of intrinsic and acquired resistance determinants in these organisms, an approach increasingly advocated in the literature on non-tuberculous mycobacterial susceptibility prediction. For now, the study stands as a careful first census: eighteen isolates, one dominant species, one frequently detected resistance-associated gene without hotspot mutations, and a handful of amino acid changes in a quinolone target that demand follow-up. In a world where antimicrobial resistance knows no boundaries between human clinics, farms, and soil, even the humblest environmental mycobacterium from a cow’s gut deserves that kind of attention.

Subject of Research: Molecular identification of non-tuberculous mycobacteria from bovine clinical samples and profiling of resistance-associated genes

Article Title: Molecular identification and resistance-associated gene profiling of non-tuberculous mycobacteria isolated from bovine clinical samples

Article References: Panigrahi, B., Narang, D., Chandra, M., Narang, A., Gupta, K., & Singh, S. T. (2026). Molecular identification and resistance-associated gene profiling of non-tuberculous mycobacteria isolated from bovine clinical samples. Molecular Biology Reports, 53(1), Article 1640. https://doi.org/10.1007/s11033-026-12814-7

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12814-7

Keywords: non-tuberculous mycobacteria, Mycobacterium vaccae, bovine tuberculosis, rpoB, katG, gyrA, antimicrobial resistance, PCR, cattle, diagnostics, genotypic variation, India